In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are used in the collection, preparation, and examination of specimens taken from the human body. This includes Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers, Oncology and Reproductive Health Diagnostics. Breast Cancer Type 1 (BRCA1) and Breast Cancer Type 2 (BRCA2) gene tests, under the overall umbrella of BRCA Tests, are carried out to detect gene rearrangements within blood samples; the outcome of which may guide therapies and prophylactic actions to treat or prevent certain types of breast and ovarian cancer. GlobalData uses proprietary data and analytics to provide a comprehensive report on the brca tests devices market, including market shares of different players within France. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the brca tests market in France was MRC-Holland and Agilent Technologies.
Only BRCA Tests ordered by physicians, genetic counselors, or as part of government screening programs are considered. Direct-to-consumer Genetic Tests performed for average-risk individuals are not included. BRCA Tests include BRCA Sanger Sequencing Tests , BRCA Multiplex Ligation-Dependent Probe Amplification Tests, and BRCA Other Tests which includes array Comparative Genomic Hybridisation (aCGH), nucleic acid amplification tests (NAATs), and Mass Array.
The value of the brca tests devices market within France was expected to be over $0.3m in 2023.
For the latest complete market share analysis of brca tests device market in France, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
